Track topics on Twitter Track topics that are important to you
Here’s a look at some of the most intriguing biopharma news developments this week from an investment in a new approach for early diagnosis of Alzheimer’s disease to reports highlighting flaws in the FDA’s accelerated drug and device approval programs.
Original Article: Four intriguing biopharma developments this weekNEXT ARTICLE
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...